Liver X Receptor
- Inhibitory Selectivity
- Liver X Receptor Inhibitors (5)
- New Liver X Receptor Products
|Catalog No.||Information||Product Use Citations||Product Validations|
GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
a. Western blot analysis for EpCAM, PKM2, and CK19 expression in livers from C57BL/6J mice treated with DDC for 1 week in the absence or presence of GW3965 (10 mg/kg; n = 4 per group). *P < 0.05, **P < 0.01. c Western blot analysis of p-STAT3, t-STAT3, and SOCS3 in WB-F344 cells treated with GW3965 (5 μM) or DMSO as control in response to IL-6 (50 ng/ml) treatment for 0, 0.25, 0.5, 0.75, 1, and 2 h.
T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively.
(C) Cells were pretreated with DMSO or T0901317 (5 μM), then incubated with 100 mg/L ox-LDL for 6 h.
RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
SR9243 is a potent and selective LXR inverse agonist.